Top

Published in:

01-10-2018 | PRECLINICAL STUDIES

Preclinical investigation of a potent geranylgeranyl diphosphate synthase inhibitor

Authors: Staci L. Haney, Yashpal S. Chhonker, Michelle L. Varney, Geoffrey Talmon, Daryl J. Murry, Sarah A. Holstein

Published in: Investigational New Drugs | Issue 5/2018

Summary

Geranylgeranyl diphosphate synthase (GGDPS) is the enzyme in the isoprenoid biosynthesis pathway that catalyzes the synthesis of the 20-carbon isoprenoid GGPP, which serves as the isoprenoid donor for protein geranylgeranylation reactions. Rab proteins mediate vesicle trafficking within the cell and their activity is dependent on geranylgeranylation. Our prior work has demonstrated that agents that disrupt Rab geranylgeranylation disrupt monoclonal protein trafficking in myeloma cells, resulting in induction of the unfolded protein response pathway and apoptosis. VSW1198 is a potent GGDPS inhibitor with measurable cellular activity at concentrations as low as 30 nM. Due to its potent activity against myeloma cells in vitro, we were interested in evaluating the toxicology profile, pharmacokinetic (PK) profile, tissue distribution pattern and metabolic stability of VSW1198 in preparation for in vivo efficacy studies. Single dose testing via IV administration in CD-1 mice revealed a maximum tolerated dose of 0.5 mg/kg. Doses ≥1 mg/kg resulted in liver toxicity that peaked around 6–7 days post-injection. Disruption of protein geranylgeranylation following repeat dosing of VSW1198 was confirmed via immunoblot analysis of unmodified Rap1a in multiple organs. The PK studies revealed a half-life of 47.7 ± 7.4 h. VSW1198 was present in all tested tissues with the highest levels in the liver. In both human liver microsomes and mouse S9 studies VSW1198 showed complete stability, suggesting no phase I or phase II metabolism. In summary, these studies demonstrate systemic distribution, on-target disruption of protein geranylgeranylation, and metabolic stability of a potent GGDPS inhibitor VSW1198 and form the basis for future efficacy studies in mouse models of myeloma.

Available only for authorised users

Gomes AQ, Ali BR, Ramalho JS, Godfrey RF, Barral DC, Hume AN, Seabra MC (2003) Membrane targeting of Rab GTPases is influenced by the prenylation motif. Mol Biol Cell 14(5):1882–1899. https://doi.org/10.1091/mbc.E02-10-0639 CrossRefPubMedPubMedCentral

Holstein SA, Hohl RJ (2011) Isoprenoid biosynthetic pathway inhibition disrupts monoclonal protein secretion and induces the unfolded protein response pathway in multiple myeloma cells. Leuk Res 35(4):551–559. https://doi.org/10.1016/j.leukres.2010.08.008 CrossRefPubMed

Obeng EA, Carlson LM, Gutman DM, Harrington WJ Jr, Lee KP, Boise LH (2006) Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 107(12):4907–4916. https://doi.org/10.1182/blood-2005-08-3531 CrossRefPubMedPubMedCentral

Wills VS, Allen C, Holstein SA, Wiemer DF (2015) Potent triazole bisphosphonate inhibitor of geranylgeranyl diphosphate synthase. ACS Med Chem Lett 6(12):1195–1198. https://doi.org/10.1021/acsmedchemlett.5b00334 CrossRefPubMedPubMedCentral

Matthiesen RA, Wills VS, Metzger JI, Holstein SA, Wiemer DF (2016) Stereoselective synthesis of homoneryl and homogeranyl triazole bisphosphonates. J Org Chem 81(19):9438–9442. https://doi.org/10.1021/acs.joc.6b01693 CrossRefPubMedPubMedCentral

Allen C, Kortagere S, Tong H, Matthiesen RA, Metzger JI, Wiemer DF, Holstein SA (2017) Olefin isomers of a triazole bisphosphonate synergistically inhibit geranylgeranyl diphosphate synthase. Mol Pharmacol 91(3):229–236. https://doi.org/10.1124/mol.116.107326 CrossRefPubMedPubMedCentral

Zhou X, Ferree SD, Wills VS, Born EJ, Tong H, Wiemer DF, Holstein SA (2014) Geranyl and neryl triazole bisphosphonates as inhibitors of geranylgeranyl diphosphate synthase. Bioorg Med Chem 22(9):2791–2798. https://doi.org/10.1016/j.bmc.2014.03.014 CrossRefPubMedPubMedCentral

Chhonker YS, Haney SL, Matthiesen RA, Wiemer DF, Holstein SA, Murry DJ (2018) Quantitative determination of a potent geranylgeranyl diphosphate synthase inhibitor using LC-MS/MS: derivatization and application. J Pharm Biomed Anal 153:22–28. https://doi.org/10.1016/j.jpba.2018.02.010

Berndt N, Sebti SM (2011) Measurement of protein farnesylation and geranylgeranylation in vitro, in cultured cells and in biopsies, and the effects of prenyl transferase inhibitors. Nat Protoc 6(11):1775–1791. https://doi.org/10.1038/nprot.2011.387 CrossRefPubMedPubMedCentral

10.

Maalouf MA (2006) Synthesis of isoprenoids incorporating a fluorescent label and evaluation of their effect on the mevalonate pathway. University of Iowa,

11.

Reilly JE, Neighbors JD, Hohl RJ (2017) Targeting protein geranylgeranylation slows tumor development in a murine model of prostate cancer metastasis. Cancer Biol Ther 18(11):872–882. https://doi.org/10.1080/15384047.2016.1219817 CrossRefPubMed

12.

Reilly JE, Neighbors JD, Tong H, Henry MD, Hohl RJ (2015) Targeting geranylgeranylation reduces adrenal gland tumor burden in a murine model of prostate cancer metastasis. Clin Exp Metastasis 32(6):555–566. https://doi.org/10.1007/s10585-015-9727-0 CrossRefPubMedPubMedCentral

13.

Lu J, Chan L, Fiji HD, Dahl R, Kwon O, Tamanoi F (2009) In vivo antitumor effect of a novel inhibitor of protein geranylgeranyltransferase-I. Mol Cancer Ther 8(5):1218–1226. https://doi.org/10.1158/1535-7163.mct-08-1122 CrossRefPubMedPubMedCentral

14.

Agabiti SS, Li J, Wiemer AJ (2017) Geranylgeranyl diphosphate synthase inhibition induces apoptosis that is dependent upon GGPP depletion, ERK phosphorylation and caspase activation. Cell Death Dis 8(3):e2678. https://doi.org/10.1038/cddis.2017.101 CrossRefPubMedPubMedCentral

15.

Barney RJ, Wasko BM, Dudakovic A, Hohl RJ, Wiemer DF (2010) Synthesis and biological evaluation of a series of aromatic bisphosphonates. Bioorg Med Chem 18(20):7212–7220. https://doi.org/10.1016/j.bmc.2010.08.036 CrossRefPubMed

16.

Agabiti SS, Liang Y, Wiemer AJ (2016) Molecular mechanisms linking geranylgeranyl diphosphate synthase to cell survival and proliferation. Mol Membr Biol:1–11. https://doi.org/10.1080/09687688.2016.1213432

17.

Haney SL, Wills VS, Wiemer DF, Holstein SA (2017) Recent advances in the development of mammalian geranylgeranyl diphosphate synthase inhibitors. Molecules 22(6):886. https://doi.org/10.3390/molecules22060886 CrossRef

18.

Osborn-Heaford HL, Murthy S, Gu L, Larson-Casey JL, Ryan AJ, Shi L, Glogauer M, Neighbors JD, Hohl R, Brent Carter A (2015) Targeting the isoprenoid pathway to abrogate progression of pulmonary fibrosis. Free Radic Biol Med 86:47–56. https://doi.org/10.1016/j.freeradbiomed.2015.04.031 CrossRefPubMedPubMedCentral

Title: Preclinical investigation of a potent geranylgeranyl diphosphate synthase inhibitor
Authors: Staci L. Haney
Yashpal S. Chhonker
Michelle L. Varney
Geoffrey Talmon
Daryl J. Murry
Sarah A. Holstein
Publication date: 01-10-2018
Publisher: Springer US
Published in: Investigational New Drugs / Issue 5/2018
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI: https://doi.org/10.1007/s10637-018-0571-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Summary

Please log in to get access to this content

Other articles of this Issue 5/2018

A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors

Phase I study of CKD-581, a pan-histone deacetylase inhibitor, in patients with lymphoma or multiple myeloma refractory to standard therapy

Comparison of published and unpublished phase I clinical cancer trials: an analysis of the CliniclTrials.gov database

GLP overexpression is associated with poor prognosis in Chronic Lymphocytic Leukemia and its inhibition induces leukemic cell death

First-in-human phase I dose escalation study of MK-8033 in patients with advanced solid tumors

Crizotinib-induced simultaneous multiple cardiac toxicities

Keynote webinar | Spotlight on antibody–drug conjugates in cancer